SKIBSTED RUSSELL 4

What Happened Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals (PCSA), reported a purchase of 1,984 shares on 2026-04-15 at $2.97 per share, totaling $5,892. The Form 4 transaction is coded "P" (purchase), reported as an open market or private purchase. This is a purchase (a cash outflow by the insider), which some investors view as a modest positive signal.

Key Details

• Transaction date and price: 2026-04-15 — 1,984 shares at $2.97 each.
• Total value: $5,892.
• Transaction code: P (purchase; open market or private purchase per filing).
• Shares owned after transaction: not specified in the filing.
• Filing date/timeliness: Form 4 filed 2026-04-17 — appears timely (filed within the two-business-day window).
• No footnotes (e.g., 10b5-1, tax withholding) were disclosed in the provided transaction detail.

Context

• Insider purchases like this are straightforward cash purchases of stock; they do not disclose motive. Small purchases (here under $6K) are routine and provide limited signal on their own.
• Retail investors may track repeated or larger insider buys for stronger signals; a single modest purchase is informational but not conclusive.